Head and Neck Cancer News and Research RSS Feed - Head and Neck Cancer News and Research

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy. [More]
Advances in head and neck cancer treatments: an interview with Prof. Argiris

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Patients with head and neck cancer usually present with locally advanced disease and often require more than one type of treatment, which may include surgery, radiotherapy, and chemotherapy. [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Broccoli sprout extract may help prevent cancer recurrence in head and neck cancer survivors

Broccoli sprout extract may help prevent cancer recurrence in head and neck cancer survivors

Potent doses of broccoli sprout extract activate a "detoxification" gene and may help prevent cancer recurrence in survivors of head and neck cancer, according to a trial by the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, confirming preliminary results presented last year at the American Association for Cancer Research Annual Meeting. [More]
Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Cancer immunology is all about how your immune cells are going to fight and kill your tumor cells. If you look at the pure genetic code of a T-cell that's going to kill your tumor compared to the same cell that has been “put-to-sleep” (by the tumor), the pure genetic DNA content of those two cells are identical. [More]
Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
Radiotherapy needs likely to increase in all European countries by 2025

Radiotherapy needs likely to increase in all European countries by 2025

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology. [More]
Innovative scanning-led surveillance can help identify need for neck dissection

Innovative scanning-led surveillance can help identify need for neck dissection

Head and neck cancer patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells, as research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection. [More]
New clinical trial launched to test potential drug that could help immune system combat cancer

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours. [More]
Majority of LAHNC patients rely on lifestyle-altering cost-coping strategies to manage treatment

Majority of LAHNC patients rely on lifestyle-altering cost-coping strategies to manage treatment

The majority of patients with locally advanced head and neck cancers (LAHNC) rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Induction chemotherapy fails to improve survival in head and neck cancer patients

Induction chemotherapy fails to improve survival in head and neck cancer patients

Head and neck cancer patients who receive chemotherapy prior to radiation therapy (induction chemotherapy or IC) rather than the standard treatment that combines chemotherapy with radiation (chemoradiation or CRT) show no survival benefit and are less likely to receive a full course of radiation, according to research from the University of Colorado Cancer Center presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients. [More]
Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss scheduled radiation therapy appointments have worse outcomes

Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine's NCI-designated Albert Einstein Cancer Center have found. [More]
Advertisement